Detrimental effects of 2-arachidonoylglycerol on whole blood platelet aggregation and on cerebral blood flow after a focal ischemic insult in rats

Abstract

This version is available at https://strathprints.strath.ac.uk/62815/ Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.ukThe Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the management and persistent access to Strathclyde's intellectual output. RESEARCH ARTICLE Integrative Cardiovascular Physiology and PathophysiologyDetrimental effects of 2-arachidonoylglycerol on whole blood platelet aggregation and on cerebral blood flow after a focal ischemic insult in rats Shearer JA, Coker SJ, Carswell HVO. Detrimental effects of 2-arachidonoylglycerol on whole blood platelet aggregation and on cerebral blood flow after a focal ischemic insult in rats. Am J Physiol Heart Circ Physiol 314: H967-H977, 2018. First published January 5, 2018; doi:10.1152/ajpheart.00299.2017.-2-Arachidonoylglycerol (2-AG) is a major modulator of blood flow and platelet aggregation and a potential neuroprotectant. The present study investigated, for the first time, the effects of 2-AG on cerebral blood flow (CBF) in the first critical hours during middle cerebral artery occlusion (MCAO) and on platelet aggregation in rats. Adult male Sprague-Dawley rats (n ϭ 30) underwent permanent MCAO under isoflurane anesthesia and were randomly assigned to receive either 2-AG (6 mg/kg iv), monoacylglycerol lipase inhibitor JZL-184 (10 mg/kg iv), or vehicle (n ϭ 6 rats/group) treatment. CBF and cardiovascular responses were measured, by a blinded investigator, for up to 4 h. In separate experiments, platelet aggregation by 2-AG (19 -300 M) was assessed by whole blood aggregometry (n ϭ 40). 2-AG and JZL-184 significantly increased the severity of the CBF deficit versus vehicle (20.2 Ϯ 8.8% and 22.7 Ϯ 6.4% vs. 56.4 Ϯ 12.1% of pre-MCAO baseline, respectively, P Ͻ 0.05) but had no effect on blood pressure or heart rate. While JZL-184 significantly increased the number of thrombi after MCAO, this did not reach significance by 2-AG. 2-AG induced platelet aggregation in rat whole blood in a similar manner to arachidonic acid and was significantly reduced by the cyclooxygenase inhibitors indomethacin and flurb...

Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism

“…Its levels in WKY and SHAM were 220 and 75 times higher than the concentration of the best-known endocannabinoid AEA, respectively. This is an important observation in the light of recent publications that 2-AG in vivo worsens heart function after acute myocardial infarction [47], increases the severity of the cerebral blood flow deficit [55] or promotes atherogenesis [56] on the one hand but ameliorates inflammatory stress-induced insulin resistance in cardiomyocytes on the other [57]. Unfortunately, there are only limited data regarding the cardiovascular effects of endocannabinoids other than 2-AG and AEA.…”

Endocannabinoid response in acute ischemic stroke: elevated 2-arachidonoylglycerol

“…In vitro experiments have demonstrated that 2-AG acts as a platelet agonist, promotes platelet activation and aggregation and is also released by the activated platelets 33 34 ; this finding was validated in vivo with a murine study where exogenous 2-AG administration (micromolar doses) induced platelet aggregation and worsened cerebral blood flow in the first hour of middle cerebral artery occlusion 35 . In our study we also observed that all patients who underwent embolectomy (all procedures resulted in successful recanalization) did not have significant elevations of 2-AG in the subacute phase.…”

The endocannabinoid system and stroke: A focused review

“…has demonstrated an intimate connection between poststroke CBF and 2-AG signaling, and further work should be done to unpack this relationship in order to better predict the full effects of endocannabinoid therapeutics in human. [31] Second, Rivers-Auty et al . have cast doubt on the idea that CB2 agonism can reduce brain damage associated with hypoxia-ischemia, and further work is needed to examine the true potential of CB2 agonism as a promising poststroke neuroprotectant.…”

“…performed blinded measurements of CBF. [31] They found that CBF was severely reduced in the 2-AG group when compared to vehicle controls for up to 4 h following the ischemic insult. These results further suggest that blocking the effects of 2-AG, the main endogenous ligand for CB1R and CB2R could play a neuroprotective role in stroke.…”